Inadequate T-cell chimerism following reduced-intensity conditioning transplantation may contribute to graft rejection and disease relapse. Anti-thymocyte globulin (ATG) enhances early donor T-cell chimerism, but may also deplete donor T cells, increasing risks of infection and relapse. We prospectively tested administration of rabbit ATG (rATG) ⩾ 14 days before the infusion of the graft, followed by in vivo decay of active rATG levels, to selectively deplete host T cells. Twenty-three patients received rATG total dose 4.5 mg/kg on days − 16 and − 15, fludarabine 30 mg/m 2 per day on day − 7 through − 3, IV busulfan 130 mg/m 2 per day on days − 4 and − 3 and cyclophosphamide 1500 mg/m 2 on day − 2. rATG levels were therapeutic in all patients on day − 14, but were sub-therapeutic (o 1 μg/mL) by day 0 in 82% of patients. Median donor T-cell chimerisms on days 30 and 180 were 100% (75-100%) and 100% (90-100%), respectively. Non-relapse mortality and relapse/progression at 48 months were 17 and 30%. Cumulative incidences of acute GvHD grades II-IV and III-IV were 39 and 9%. Median follow-up is 64 months (46-79 months). Survival and disease-free survival at 48 months were 70 and 52%. These data suggest that selective depletion of host T cells using this regimen is a feasible and effective strategy.
INTRODUCTION
Reduced intensity conditioning transplant (RICT) regimens expand access to and reduce the toxicity of allogeneic stem cell transplantation. However, some RICT regimens may be significantly less immunoablative than conventional myeloablative regimens. [1] [2] [3] Limited host immunoablation may result in mixed or low-level donor T-cell chimerism in the early post-transplant period, which may in turn increase the risk of graft rejection or malignant relapse following allogeneic hematopoietic cell transplantation. 1, [4] [5] [6] [7] [8] [9] Serotherapy with polyclonal anti-lymphocyte Ab preparations such as rabbit-or horse-derived anti-thymocyte globulin (ATG) has been used by several investigators to increase the immunosuppressive efficacy of RIC regimens without the toxicity associated with additional cytotoxic chemotherapy or irradiation. Whereas this can be effective at decreasing the risk of graft rejection effected by surviving host-derived T lymphocytes, the persistence of active ATG during and after the infusion of the graft can result in significant in vivo depletion of donor T lymphocytes. Although potentially beneficial in reducing the risk of GvHD, such in vivo depletion of donor lymphocytes may also eliminate donor T cells responsible for graft-versus malignancy effects and anti-infection immunity post transplant. Thus, although rates of acute and chronic GvHD may be lower in patients receiving ATG, it has been suggested that such therapy may produce inferior results with respect to rates of relapse, infection and disease-free survival (DFS), 10 although this effect may depend upon the dose of ATG used. 11, 12 ATG is conventionally administered at the same time as other elements of the preparative regimen and immediately before the infusion of the graft. This results in depletion of both host and donor T cells in transplanted patients. Rabbit ATG (rATG) levels decline fairly rapidly following administration. 13, 14 We hypothesized that if a reduced dose of a rATG preparation (Thymoglobulin) were instead administered approximately 2 weeks before the infusion of the graft, in vivo decay of active rATG levels before the infusion of the graft would result in selective depletion of host cellular immunity while sparing donor T cells. We postulated that this regimen would result in high levels of donor T-cell chimerism in the early post-transplant period without resulting in severe post-transplant immunosuppression and associated infections. The results of a prospective clinical trial designed to test this hypothesis are reported herein.
PATIENTS AND METHODS

Patient eligibility
Patients aged ⩽ 75 years with a hematologic malignancy in need of allogeneic transplantation were included in this study. Patients with an HLA-identical sibling donor were included in this study, whereas patients with matched unrelated donors were enrolled on an alternative clinical trial designed to reduce GvHD. Patients who were enrolled had adequate vital organ function (bilirubin, aspartate transaminase, alanine transaminaseo5 times upper limit of normal; creatinine ⩽ 2.0 mg/dL; left ventricular ejection fraction ⩾ 40%, DLCO ⩾ 40%, FEV1 ⩾ 50%), KPS460%, no active serious infections including HIV, no central nervous system involvement by malignancy and no prior chronic use of immunosuppressive drugs.
Study design and treatment
This prospective open label phase II trial was approved and monitored by the Institutional Review Board of Northside Hospital. The regimen used was as follows: rATG (Thymoglobulin, Genzyme, Cambridge, MA, USA) 1 mg/kg over 4-6 h on day − 16 and 3.5 mg/kg over 6-8 h on day − 15 (total dose 4.5 mg/kg), fludarabine 30 mg/m 2 per day × 5 days over 30 min on days − 7 to − 3, busulfan IV (Busulfex) 130 mg/m 2 per day × 2 days over 3 h on days − 4 and − 3 and cyclophosphamide 1500 mg/m 2 × 1 day on day − 2. G-CSF mobilized PBSCs (CD34+ cell dose 2-8 × 10 6 /kg) were administered on d 0. Methylprednisone was used to pre-medicate the infusion of rATG (1 mg/kg on days − 16 and − 15, with a tapering dose continued through day − 8. GvHD prophylaxis consisted of tacrolimus and methotrexate. Tacrolimus was dosed to maintain a blood level of 8-12 ng/mL through day 90 with a subsequent taper to discontinue by day 150 in patients without active GvHD. Methotrexate was administered at a dose of 5 mg/m 2 on days 1, 3 and 6. Methotrexate dose was held in patients with a creatinine43.0 mg per day or ⩾ grade 3 mucositis on the day of administration. G-CSF was given starting on day 7 at a dose of 5 μg/ kg per day and continued until the ANC was 41000/μL for 3 consecutive days or 1500/μl for 1 day. Antimicrobial prophylaxis was not prescribed by the protocol but was administered according to our institutional standard. CMV reactivation was monitored using quantitative PCR and treated preemptively according to the institutional standards. EBV reactivation was not routinely monitored. All patients were admitted on days − 16 and − 15 for rATG administration but then discharged to receive the remaining therapy in the outpatient clinic if clinically feasible. Patients at high risk of veno-occlusive disease received ursodiol with or without enoxaparin beginning day − 5 and continuing through day +30. Phenytoin was used as anti-seizure prophylaxis day − 5 to − 1. Patients who failed to achieve a CR or failed to achieve full (490%) donor T-cell chimerism by the 3-month assessment post transplant, or subsequently demonstrated progression of malignancy and had no evidence of active GvHD, were eligible for donor leukocyte infusions (DLIs) at the discretion of the treating physician.
Evaluations
Chimerism analysis of peripheral blood mononuclear cells using PCR for STR was performed on days 15, 30, 60, 90, 180 and 360. The peripheral blood cells were separated into the T-cell component (using CD3-based selection) and the myeloid component (using CD33-based selection) to 495% purity by immunomagnetic bead selection before assessment of chimerism. Reassessment of malignancy was performed according to disease-specific criteria on at least 3, 6, 12, 18 24 and 36 months post allografting and at additional time points as necessitated by clinical assessment. GvHD was assessed and documented by a single dedicated nurse. Chronic GvHD was graded according to national consensus criteria. 15 
Measurement of rATG levels
Samples for measurement of rATG levels were obtained from patients on days − 14, − 7 and 0. The concentrations were measured by Genzyme Corporation (Framingham, MA, USA). Total anti-thymocyte globulin (ATG) was quantified by ELISA using anti-ATG polyclonal Abs to capture and to detect ATG present in serum samples. Total ATG levels (μg/mL) in serum were reported relative to an ATG standard curve. The limit of quantification for total ATG is 3.9 μg/mL and the overall precision is o20% CV throughout the range of the standard curve.
Active ATG (bound to human peripheral blood mononuclear cells) was quantified by a flow cytometric method using anti-ATG FITC-conjugated polyclonal Ab. The concentration of active ATG was determined based on median fluorescence intensity quantified against an ATG standard curve. Serum samples from normal donors had levels of total and active ATG below the assay limit of quantifications.
Statistical analysis
The primary end point was peripheral blood T-cell (CD3) chimerism on day 30. The study sample size was powered to demonstrate an increase in full donor (495%) T-cell chimerism from a baseline of o45% of patients in prior trials using reduced-dose busulfan regimens to the anticipated value of 480% patients with an alpha error of 0.1 and a power of 90%. The outcome was death for overall survival and was relapse/progression or death in remission for DFS. The probabilities of overall survival and DFS were estimated by the Kaplan-Meier method. The 95% confidence interval was calculated using the log-log transformation. The cumulative incidence method was used to determine the rates of acute and chronic GvHD, nonrelapse mortality and relapse/progression. Non-relapse mortality and relapse/progression were treated as competing risks. Descriptive statistics were used for categorical variables
RESULTS
Patient characteristics
Twenty-three patients were entered on this study between April 2007 and May 2010. Their characteristics are shown in Table 1 . Eight patients had undergone a prior autotransplant at a median of 498 days (range 308-1998 days) previously. Non-Hodgkin lymphoma (NHL) was the most frequent diagnosis (5 diffuse large B cell, 3 follicular grade 2, 1 follicular grade 3 and 1 peripheral T cell). Six patients had myelodysplasia (MDS; IPSS-intermediate 1 (three patients); intermediate 2 (three patients)). Seven patients were in CR at the time of enrollment (4 CR1 (2 AML, 1 NHL and 1 MDS), 2 CR2 (1 NHL, 1 myeloma) and 1 CR3 (NHL)). Six patients had less than a PR to therapy given immediately before the enrollment (3 MDS, 1 MPD, 1 HL and 1 NHL) and two patients had untreated disease before the transplantation (both MDS). ATG levels Measured levels of active rATG for each patient are shown in Figure 1 . All evaluable patients had a therapeutic active rATG level on day − 14 (median 4.4 μg/mL (range 1.37-12.2). However, the active rATG level had decayed to sub-therapeutic levels (o 1 μg/mL) in 14 of 17 evaluable cases (82%) by day 0 (median 0.5 μg/mL, range 0-3.2), implying that in these cases, donor T cells infused would not be exposed to depleting doses of residual rATG.
Chimerism
Box plots of donor chimerism for peripheral blood CD3+ cells and CD33+ cells are shown in Figure 2 . Median (range) donor Abbreviations: MDS = myelodysplasia; MPD = myeloproliferative disorder; NHL = non-Hodgkin lymphoma.
Selective
, 180 and 360 post transplant were 94% (74-100), 100% (75-100), 100% (87-100), 100% (76-100), 100% (90-100) and 100% (100-100), respectively. Median donor chimerism for peripheral blood myeloid (CD33+) cells was 100% at all time points measured. Patients with an active ATG level of 41 μg/mL on day 0 (n = 3) did not have lower T-cell chimerisms than patients with a level ⩽ 1 μg/mL on day 0. Median T-cell chimerism on day 30 were 95% vs 93%, respectively (P = 0.24).
Additional cellular therapy One patient received CD34+ selected cells (2.36 × 10 6 CD34+ cells per kg) from the original donor for chronic severe cytopenias 176 days post transplant in the presence of complete donor T-cell chimerism. This patient is currently alive with improved blood counts. The second patient received DLI on two occasions for residual disease (1 × 10 7 and 4 × 10 7 CD3+ cells per kg, respectively). She refused further staging and expired 4 months following the second DLI of pseudomonas sepsis. The final patient received chemotherapy followed by two doses of DLI 3 months apart (1 × 10 7 CD3 and 5.1 × 10 7 CD3) for disease progression and is currently alive in CR3.
GvHD Maximum cumulative incidences of acute GvHD grade II-IV and grade III-IV were 39% and 9%, respectively (Figure 3a) . Maximum cumulative incidences of extensive chronic GvHD and severe chronic GvHD were 60% and 35%, respectively (Figure 3b ).
Infections
The following post-transplant infections were documented in patients enrolled on this trial-bacterial: bacteremia-methicillinresistant Staphylococcus epidermidis (n = 17), methicillin-resistant Staphylococcus aureus (n = 1), Gram-positive organisms (other; n = 9) and other bacteria (n = 5) Clostridium difficile diarrhea (n = 3). Non-relapse mortality, overall survival and progression-free survival Cumulative incidences of non-relapse mortality at 6, 12 and 24 and 48 months were 4%, 9%, 13% and 17%, respectively. Cumulative incidence of relapse/progression of malignancy at 48 months is 30% (Figure 4a ). Estimated probabilities of survival and DFS at 48 months were 70 and 52% (Figure 4b ).
Patient status
Fifteen patients are currently alive and eight patients are deceased. Causes of death were chronic GvHD and its treatment (four patients), relapse of malignancy (three patients), and bacterial infection (one patient).
DISCUSSION
It has previously been demonstrated that when given at a dose of 6 mg/kg, rATG levels decay with first-order and second-order kinetics such that the T 1/2 of active rATG is 7 days and the level reaches a sub-therapeutic value ( o1 μg/mL) at~17-20 days post infusion. 13, 14 In our study, we administered the rATG at a lower dose (4.5 mg/kg) on days − 16 and − 15 of the transplant and assessed whether active rATG levels would decline to a subtherapeutic level by the day of infusion of donor cells. Consistent with our hypothesis, active rATG levels were sub-therapeutic (o 1 μg/mL) by day 0 in 82% of assessed patients treated on this study. The remaining patients had active rATG levels only slightly above this value. To our knowledge, this is the only study to effectively use dose and timing of administration of rATG to selectively deplete host but not donor T cells during conditioning for allogeneic hematopoietic transplantation. In a study designed to utilize the power of natural killer T cells to prevent GvHD, Lowsky et al. 16 used a total dose of 7.5 mg/kg administered between days − 11 and − 7 before transplant. However, in their study, therapeutic levels of active rATG were observed between day 0 and day 7 likely causing significant depletion of donor T cells. Although relatively high median levels of donor T-cell chimerism were seen on this trial by day 30, the relative contribution of the dose and timing of rATG and the TLI used pre-transplant in this study is difficult to assess.
Despite the reduced-intensity preparative regimen used and its excellent tolerability, high levels of donor T-cell chimerism were achieved from the earliest time points analyzed. Specifically, median donor T-cell chimerism was 100% starting at day 30 post transplant and all patients achieved at least 75% donor chimerism by day 30. Lineage-specific chimerism studies are not always reported in published studies of RICT. Where reported, relatively low levels of early donor T-cell chimerism were found using some preparative regimens. [1] [2] [3] For example, in CALGB 100002, a trial that used an identical preparative regimen to that used in our study without rATG or low-dose cyclophosphamide, only 23% of matched sibling donor patients achieved ⩾ 90% donor chimerism in peripheral blood T cells by day 30 post transplant. 1 In another report, the use of a regimen comprised of fludarabine 150 mg/m 2 and oral busulfan 10 mg/kg, complete donor T-cell chimerism was seen in 0% on day 30 and 20% on day 90, whereas granulocytes demonstrated complete donor chimerism from day 30 in nearly all cases. 3 It is probable that the preferential depletion of host T cells effected by our strategy contributed to the much improved levels of donor T-cell chimerism seen in our study, although the relative impact of the addition of rATG and low-dose cyclophosphamide cannot be dissected by this study and can be assessed in a future prospective trial comparing this regimen with one without rATG. The regimen reported in our study could also be compared directly with the same regimen modified to administer rATG in the conventional way-immediately before the infusion of donor cells. This would specifically assess the effect of combined in vivo depletion of both recipient and donor T cells versus selective depletion of recipient T cells as affected by our regimen.
Several investigators have demonstrated that low levels of donor T-cell chimerism are associated with an increased risk of graft rejection and relapse of malignancy.
1,4-8 For example, Baron et al. 4 assessed donor T-cell chimerism in 322 patients receiving matched grafts after non-myeloablative conditioning. In a multivariate analysis, achievement of complete donor chimerism was associated with a significantly lower risk of relapse (hazard ratio: 0.5; P = 0.002). Saito et al. 7 found that in 117 patients undergoing busulfan-containing RICT that decreased levels of donor T-cell chimerism on day 30 post transplant was associated with a higher risk of graft rejection, and poorer overall and event-free survival. In CALGB study 100002 1 , event-free survival was superior in patients achieving full donor T-cell chimerism by day 30. Consistent with the poor levels of early T-cell chimerism achieved in that trial, rates of overall survival and event-free survival (47% and 29% at 2 years, respectively) were much lower than seen in our study (70% and 52% at 4 years, respectively). Although patient selection differences may have contributed to the different outcomes seen, it is also feasible that the high rate of early full donor T-cell chimerism effected by the regimen used in our study contributed to better outcomes seen. Despite the use of rATG, rates of viral and fungal infections seen in our study were relatively low and in many cases were associated with the treatment of GvHD. This supports the hypothesis that sub-therapeutic levels of active rATG on day 0 result in minimal if any depletion of donor T cells, thus retaining the contribution of such cells to post-transplant immunity against infections.
Also, consistent with relative sparing of donor T cells by our regimen was the observation that the rates of acute and chronic GvHD in our study were not lower than that seen in CALGB trial 100002 (acute GvHD 55% at day 100 and extensive chronic GvHD 36% at 2 years) where rATG was not used for matched sibling donor. 1 Some investigators have found an association between high rates of early full donor T-cell chimerism and rates of GvHD 6 while others have failed to demonstrate an association. 7 A recent study found that T-cell chimerism on day 30 correlated with the occurrence of extensive chronic but not acute GvHD. 17 Extensive chronic GvHD was seen in 60% of patients in our study but was fatal in only four patients (17%) on prolonged follow-up. Although chronic GvHD may be protective against late disease relapse, it may also impair quality of life for those affected. Among the strategies that can be investigated in the future to abrogate this risk are delayed withdrawal of immunosuppression or the prophylactic administration of rituximab 18 or bortezomib 19 to diminish the incidence of chronic GVHD while maintaining the low rates of disease relapse seen.
In summary, the regimen reported produced high levels of early donor T-cell chimerism, o 10% non-relapse mortality at 12 months, 52% DFS and 70% survival at 48 months. It should be further assessed in prospective randomized comparisons against more commonly used RICT regimens.
